NEW YORK – Molecular diagnostics instrument and assay maker Rheonix has received an expanded Emergency Use Authorization from the US Food and Drug Administration for its SARS-CoV-2 assay. The firm's test is now authorized for the use of saliva samples.
Ithaca, New York-based Rheonix obtained its initial EUA for a SARS-Cov-2 test in April.